The MR diffusion-weighted imaging technique was used to evaluate the efficacy and safety of CalliSpheres drug-loaded microspheres for transarterial chemoembolization in the treatment of advanced bladder cancer. 35 patients with advanced bladder cancer were treated with CalliSpheres DLMS for transarterial chemoembolization. Imaging techniques such as magnetic resonance (MR) diffusion-weighted imaging were used to evaluate the therapeutic effect. The changes in serum tumor markers, immune function indexes, and oxidative stress indexes in patients before and after treatment were compared, and the quality of life of patients and the incidence of adverse reactions during follow-up were also evaluated. The results showed that the overall response rate (ORR) was 74.29% and that the disease control rate (DCR) was 97.14%. Compared with that before treatment, the ADC value of the tumor in patients with advanced bladder cancer detected by MR diffusion-weighted imaging technology was significantly increased after treatment and the maximum tumor diameter was significantly decreased . Compared with those before treatment, the levels of serum tumor markers (CA199, CA724, and CA125) in advanced bladder cancer patients after treatment decreased . The levels of T-lymphocyte subsets (CD3+ and CD4+) decreased, and CD8+ levels increased . The levels of superoxide dismutase decreased . At the same time, the subscale evaluation of function, symptoms, quality of life, adverse reactions, and economics of patients with advanced bladder cancer on the QLQ-C30 scale improved after treatment, and the incidence rate and recurrence rate during the follow-up period were 8.57% and 11.43%, respectively. It showed that CalliSpheres DLMS had a good clinical effect and high safety in the treatment of advanced bladder cancer and was a safe and feasible treatment method. The use of MR diffusion-weighted imaging technology could achieve quantitative evaluation of clinical efficacy of advanced bladder cancer.

中文翻译：

---

磁共振扩散加权成像评估 CalliSpheres 载药微球治疗晚期膀胱癌的临床疗效

MR扩散加权成像技术用于评估CalliSpheres载药微球用于经动脉化疗栓塞治疗晚期膀胱癌的有效性和安全性。35 名晚期膀胱癌患者接受了 CalliSpheres DLMS 经动脉化疗栓塞治疗。使用磁共振（MR）弥散加权成像等成像技术评估治疗效果。比较患者治疗前后血清肿瘤标志物、免疫功能指标、氧化应激指标的变化，并评价患者的生活质量和随访期间的不良反应发生情况。结果显示，总缓解率（ORR）为74.29%，疾病控制率（DCR）为97.14%。. 与治疗前相比，晚期膀胱癌患者治疗后血清肿瘤标志物（CA199、CA724、CA125）水平降低. T 淋巴细胞亚群（CD3+ 和 CD4+）水平降低，CD8+ 水平升高. 超氧化物歧化酶水平下降. 同时，晚期膀胱癌患者在QLQ-C30量表上的功能、症状、生活质量、不良反应、经济等子量表评价在治疗后得到改善，随访期间的发病率和复发率期间分别为 8.57% 和 11.43%。表明CalliSpheres DLMS治疗晚期膀胱癌具有良好的临床疗效和较高的安全性，是一种安全可行的治疗方法。利用MR弥散加权成像技术可以实现对晚期膀胱癌临床疗效的定量评价。